Experimental pancreatic cancer vaccine elicits durable immune responses in high-risk participants
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low five-year survival rate. Approximately 10% of cases are associated with…
Read the full article
Comments
Sign in to join the conversation.
No comments yet. Be the first.